Latest Breaking News On - Psoriasis patients who had - Page 1 : comparemela.com

Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI® (risankizumab) in moderate to severe.

United statesChiedzo mpofuGlobal medical affairsEuropean academy of dermatologyEpidemiologic survey on prevalence of genital psoriasisBoehringer ingelheimFree communications in atopic dermatitis sessionEuropean academyAll timesPsoriasis patients participatingPsoriasis patients who hadTerm safetyIsevere plaque psoriasisInterim analysisOpen label extensionLong term risankizumab treatment